AIDDISON

GPT-Rosalind is a purpose-built frontier reasoning model developed by OpenAI to accelerate scientific research across biology, drug discovery, and translational medicine. It is designed specifically for life sciences workflows, where researchers must navigate large volumes of literature, experimental data, and specialized databases to generate and validate new ideas. It combines deep domain understanding in areas such as chemistry, genomics, protein engineering, and disease biology with advanced tool-use capabilities, allowing it to interact with scientific databases, analyze experimental outputs, and support complex, multi-step reasoning tasks. It can assist with evidence synthesis, hypothesis generation, literature review, sequence interpretation, and experimental planning, helping scientists move faster from raw data to actionable insights. GPT-Rosalind transforms complex, time-intensive research processes into more efficient AI-assisted workflows.

Recursion is a TechBio company focused on transforming drug discovery by combining biology, data, and artificial intelligence. Founded over a decade ago, the company pioneered the use of large-scale cellular imaging to train AI models that decode the biological drivers of disease. Recursion’s mission is to deliver better medicines through novel insights and precision design, reducing the high failure rates of traditional drug development. Its proprietary Recursion OS platform integrates massive biological datasets with machine learning to accelerate discovery from target identification to clinical development. The company has built an advanced pipeline of potential first-in-class and best-in-class therapies targeting aggressive cancers and rare diseases. Automated wet labs and robotics enable millions of experiments per week, feeding continuous learning into its AI models.